Communiqués Sino Biopharmaceutical Limited

Actions

1177

KYG8167W1380

Produits pharmaceutiques

Temps Différé Hong Kong S.E. Autres places de cotation 09:01:58 14/05/2026			Varia. 5j.	Varia. 1 janv.
5,510 ^HKD	-2,48 %		+1,10 %	-10,68 %

11/05	La Bourse de Hong Kong stagne face à l'impasse des négociations USA-Iran ; LDROBOT s'envole pour ses débuts	MT
11/05	GSK s'appuie sur Sino Biopharm pour commercialiser son traitement contre l'hépatite B chronique en Chine	RE

Communiqués

28/04	Sino Biopharmaceutical : Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League, Leads Delegation to Inspect Chia Tai Tianqing, Focusing on Innovative Development and Youth Talent Cultivation	PU
10/04	Sino Biopharmaceutical : Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11	PU
27/03	Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion	PU
13/03	Sino Biopharmaceutical : Positive on Dual Endpoints! CTTQ Pharma's Phase III Study of TQB3454 in Bile Duct Cancer Succeeds, Marketing Application to be Submitted	PU
16/01	Sino Biopharmaceutical : JPM 2026 \| Sino Biopharm Leads in siRNA and Tumor Innovation Platforms, M&A Integration Unleashes Long-Term Growth Momentum	PU
12/12	Sino Biopharmaceutical : World's First CDK2/4/6 Inhibitor Approved for Marketing, Culmerciclib Capsules (Saitanxin®) Reshape the Breast Cancer Treatment Landscape	PU
18/08/25	Sino Biopharmaceutical : Biopharm 2025 Interim Results Announcement	PU
13/08/24	Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results	AQ
29/04/24	Sino Biopharmaceutical : 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	PU
29/03/24	Sino Biopharm (1177.HK) Announces 2023 Annual Results	AQ
25/08/23	Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results	AQ
09/06/23	Sino Biopharmaceutical : 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	PU
31/03/23	Sino Biopharm (1177.HK) Announces 2022 Annual Results	AQ
23/08/22	Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion	AQ
26/07/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "LENVATINIB MESILATE CAPSULE" OBTAINS DRUG REGISTRATION CERTIFICATE	PU
22/07/21	Sino Biopharmaceutical : Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic	AQ
24/05/21	Sino Biopharmaceutical : 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion	AQ
13/05/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "PALONOSETRON HYDROCHLORIDE INJECTION" PASSES CONSISTENCY EVALUATION	PU
13/05/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "DASATINIB TABLET" PASSES CONSISTENCY EVALUATION	PU
10/05/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER	PU
03/05/21	Sino Biopharmaceutical : NOTIFICATION OF BOARD MEETING	PU
29/04/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "TIAN NENG" OBTAINS REGISTRATION CERTIFICATE OF FORMULA FOOD FOR SPECIAL MEDICAL PURPOSE	PU
28/04/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "SU QIAN" OBATAINS REGISTRATION CERTIFICATE OF FORMULA FOOD FOR SPECIAL MEDICAL PURPOSE	PU
22/04/21	Sino Biopharmaceutical : NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS	PU
30/03/21	Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - PENPULIMAB OBTAINED BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR THIRD-LINE TREATMENT OF METASTATIC NASOPHARYNGEAL CARCINOMA	PU